RNA m6A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia.

IF 1.5 Q3 HEMATOLOGY
Rong Yin, Yashu Li, Wen Tian, Fuling Zhou, Haojian Zhang
{"title":"RNA m<sup>6</sup>A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia.","authors":"Rong Yin,&nbsp;Yashu Li,&nbsp;Wen Tian,&nbsp;Fuling Zhou,&nbsp;Haojian Zhang","doi":"10.1097/BS9.0000000000000131","DOIUrl":null,"url":null,"abstract":"<p><p>N<sup>6</sup>-Methyladenosine (m<sup>6</sup>A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m<sup>6</sup>A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m<sup>6</sup>A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m<sup>6</sup>A biology by focusing on writers, readers, and erasers of m<sup>6</sup>A modification, and describe the development of high-throughput methods for RNA m<sup>6</sup>A mapping. We further discuss the important roles of m<sup>6</sup>A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m<sup>6</sup>A modifiers. Overall, this review provides a comprehensive summary of RNA m<sup>6</sup>A biology in acute myeloid leukemia.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742108/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"血液科学(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/BS9.0000000000000131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

N6-Methyladenosine (m6A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m6A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m6A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m6A biology by focusing on writers, readers, and erasers of m6A modification, and describe the development of high-throughput methods for RNA m6A mapping. We further discuss the important roles of m6A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m6A modifiers. Overall, this review provides a comprehensive summary of RNA m6A biology in acute myeloid leukemia.

Abstract Image

Abstract Image

Abstract Image

RNA m6A修饰:在急性髓性白血病中的定位方法、作用和机制。
n6 -甲基腺苷(m6A)是真核生物mRNA中含量最多的修饰物,通过调控RNA命运决定发挥重要的生物学功能。最近的研究表明m6A修饰在包括急性髓系白血病在内的血液系统恶性肿瘤中起关键作用。目前表观转录组学研究的增长主要得益于在转录组范围内检测RNA m6A修饰的技术进步。在这篇综述中,我们首先简要总结了RNA m6A生物学的最新进展,重点介绍了m6A修饰的“写子”、“读子”和“擦子”,并描述了RNA m6A高通量定位方法的发展。我们进一步讨论了m6A修饰剂在急性髓性白血病中的重要作用,并强调了通过靶向m6A修饰剂治疗AML的潜在抑制剂的鉴定。总之,本文综述了RNA m6A在急性髓性白血病中的生物学研究进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信